Graham Holdings
GHC
1,169.60
+11.93
+1.03%
Graham Holdings
US · GHC
#2144 by market cap
Listed 1970
1,169.60
+11.93
+1.03%
Live - 5344 symbols - heartbeat 476s ago
· 2026-10-07 19:54
After-hours
1,169.60
0.00%
- Market cap
- 4.95B
- P/E (TTM)i
- 9.46
- P/Bi
- 1.04
- EPSi
- 66.47
- Div yieldi
- 0.63%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on GHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.06, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +2.52% YoY
Margins
- Gross margin
- 29.93%
- Operating margin
- 5.03%
- Net margin
- 5.92%
Key ratios & quality
- Enterprise valuei
- 4.54B
- PEG ratioi
- 0.15
- Altman Z-Scorei
- 3.06
PEG uses trailing P/E against the 3-year net income growth rate (63.33%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.70B | 2.93B | 2.89B | 3.19B | 3.92B | 4.41B | 4.79B | 4.91B |
| Gross profit | 1.11B | 983.85M | 977.02M | 1.07B | 1.27B | 1.31B | 1.47B | 1.47B |
| Selling & admin expenses | 750.93M | 717.66M | 715.40M | 831.85M | 921.74M | 1.01B | 1.08B | 1.11B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 254.27M | 153.70M | 130.58M | 110.32M | 212.89M | 168.46M | 265.33M | 247.28M |
| Pretax profit | 323.51M | 426.48M | 407.27M | 449.63M | 121.73M | 299.00M | 1.02B | 449.67M |
| Tax | 52.10M | 98.60M | 107.30M | 96.30M | 51.30M | 87.30M | 292.10M | 146.40M |
| Net profit | 271.41M | 327.88M | 299.97M | 353.33M | 70.43M | 211.70M | 732.61M | 303.27M |
| Basic EPS | 51 | 62 | 58 | 71 | 14 | 44 | 165 | 67 |
| Diluted EPS | 50.20 | 61.21 | 58.13 | 70.45 | 13.79 | 43.82 | 163.40 | 66.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.17B | 1.22B | 1.28B | 1.25B | 1.24B | 1.30B |
| Gross profit | 346.56M | 376.33M | 374.46M | 372.53M | 378.79M | 392.03M |
| Selling & admin expenses | 270.71M | 276.69M | 276.10M | 286.70M | 277.48M | 284.14M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 47.47M | 72.75M | 69.37M | 57.69M | 76.86M | 83.63M |
| Pretax profit | 33.62M | 60.62M | 183.04M | 172.39M | 40.65M | 317.48M |
| Tax | 7.90M | 20.20M | 56.80M | 61.50M | 9.90M | 35.10M |
| Net profit | 25.72M | 40.42M | 126.24M | 110.89M | 30.75M | 282.38M |
| Basic EPS | 6 | 8 | 28 | 25 | 7 | 66 |
| Diluted EPS | 5.45 | 8.35 | 27.91 | 24.69 | 6.62 | 64.86 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.53B | 1.66B | 1.77B | 1.85B | 1.68B | 1.85B | 2.10B | 2.43B |
| Cash & ST investments | 767.84M | 800.13M | 1.00B | 970.33M | 791.73M | 866.93M | 1.12B | 1.36B |
| Inventory | 69.48M | 120.83M | 120.62M | 141.47M | 226.81M | 297.21M | 295.81M | 303.37M |
| Total assets | 4.76B | 5.93B | 6.44B | 7.43B | 6.55B | 7.19B | 7.68B | 8.40B |
| Total current liabilities | 812.16M | 1.04B | 949.65M | 1.17B | 1.15B | 1.23B | 1.20B | 1.39B |
| Short-term debt | 6.36M | 174.89M | 93.25M | 219.40M | 225.82M | 131.00M | 84.82M | 239.43M |
| Long-term debt | 470.78M | 430.65M | 506.10M | 525.75M | 570.55M | 745.08M | 721.62M | 705.62M |
| Total liabilities | 1,842,913,000.00 | 2,598,785,000.00 | 2,665,798,000.00 | 2,999,545,000.00 | 2,778,889,000.00 | 3,161,677,000.00 | 3,346,569,000.00 | 3,528,562,000.00 |
| Total equity | 2.92B | 3.33B | 3.78B | 4.43B | 3.77B | 4.03B | 4.33B | 4.87B |
| Retained earnings | 6.24B | 6.53B | 6.80B | 7.13B | 7.16B | 7.34B | 8.03B | 8.29B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.03B | 2.01B | 2.24B | 2.43B | 2.21B | 2.27B |
| Cash & ST investments | 1.07B | 1.07B | 1.20B | 1.36B | 1.11B | 1.25B |
| Inventory | 262.49M | 267.20M | 306.26M | 303.37M | 306.89M | 333.46M |
| Total assets | 7.62B | 7.62B | 7.85B | 8.40B | 8.18B | 8.14B |
| Total current liabilities | 1.25B | 1.58B | 1.69B | 1.39B | 1.23B | 1.22B |
| Short-term debt | 210.33M | 563.02M | 487.48M | 239.43M | 165.68M | 252.81M |
| Long-term debt | 715.46M | 314.25M | 307.03M | 705.62M | 714.88M | 708.90M |
| Total liabilities | 3,246,549,000.00 | 3,184,609,000.00 | 3,311,291,000.00 | 3,528,562,000.00 | 3,383,765,000.00 | 3,319,623,000.00 |
| Total equity | 4.37B | 4.43B | 4.54B | 4.87B | 4.80B | 4.82B |
| Retained earnings | 8.04B | 8.07B | 8.18B | 8.29B | 8.31B | 8.58B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 287.02M | 165.16M | 210.66M | 202.43M | 235.60M | 259.88M | 406.99M | 347.19M |
| Depreciation & amortization | 112.25M | 205.83M | 251.16M | 235.98M | 328.71M | 203.84M | 187.42M | 172.16M |
| Free cash flow | 188.83M | 71.66M | 141.07M | 39.89M | 152.92M | 166.43M | 324.08M | 275.30M |
| Dividends paid | -28.62M | -29.55M | -29.97M | -30.14M | -30.71M | -30.95M | -30.35M | -31.36M |
| Stock buybacks / issuance | -118.03M | -2.10M | -161.83M | -55.68M | -71.39M | -193.16M | -114.10M | -3.47M |
| Ending cash balance | 264.12M | 214.04M | 423.05M | 158.84M | 190.43M | 201.89M | 297.85M | 311.41M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 46.01M | 94.80M | 178.09M | 28.29M | 67.73M | 52.68M |
| Depreciation & amortization | 42.48M | 41.52M | 44.49M | 43.67M | 39.26M | 38.79M |
| Free cash flow | 30.53M | 77.99M | 161.75M | 5.03M | 48.56M | 32.62M |
| Dividends paid | -7.81M | -7.85M | -7.85M | -7.85M | -8.20M | -8.11M |
| Stock buybacks / issuance | -3.47M | 0 | 0 | 0 | -34.14M | -87.84M |
| Ending cash balance | 206.94M | 229.35M | 237.10M | 311.41M | 233.96M | 208.11M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 9.24 | 10.51 | 8.49 | 8.58 | 1.64 | 5.29 | 17.49 | 6.42 |
| ROA %i | 5.56 | 6.13 | 4.85 | 5.04 | 0.95 | 2.96 | 9.68 | 3.62 |
| ROIC %i | 8.73 | 8.88 | 7.09 | 7.23 | 2.00 | 4.80 | 15.88 | 6.33 |
| 5-year avg ROE %i | 12.77 | 6.83 | 9.24 | 9.61 | 7.68 | 6.88 | 8.29 | 7.88 |
| EBIT margin %i | 13.41 | 15.56 | 15.42 | 15.18 | 4.49 | 8.21 | 25.27 | 11.57 |
| FCF / sales %i | 7.00 | 2.44 | 4.88 | 1.25 | 3.90 | 3.77 | 6.76 | 5.61 |
| Current ratioi | 1.89 | 1.60 | 1.87 | 1.58 | 1.47 | 1.50 | 1.75 | 1.75 |
| Quick ratioi | 1.69 | 1.38 | 1.65 | 1.38 | 1.16 | 1.14 | 1.37 | 1.40 |
| Debt / assetsi | 10.02 | 18.25 | 15.96 | 15.49 | 18.16 | 17.43 | 15.23 | 15.76 |
| LT debt / equityi | 16.14 | 27.35 | 24.87 | 21.16 | 25.84 | 28.22 | 25.48 | 22.60 |
| Interest coveragei | 9.54 | 15.32 | 11.63 | 14.25 | 3.24 | 5.72 | 6.50 | 4.79 |
| Revenue CAGR (3Y) %i | 1.40 | 5.71 | 3.69 | 5.72 | 10.21 | 15.18 | 14.57 | 7.77 |
| Net income CAGR (3Y) %i | -- | 24.82 | -0.19 | 9.09 | -41.07 | -11.91 | 27.20 | 63.33 |
| FCF CAGR (3Y) %i | -- | -28.33 | -12.10 | -40.44 | 28.74 | 5.66 | 101.03 | 21.65 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 14.87 | 16.28 | 17.20 | 6.42 | 6.55 | 11.82 |
| ROA %i | 8.34 | 9.12 | 9.53 | 3.62 | 3.75 | 6.84 |
| ROIC %i | 14.52 | 14.68 | 15.50 | 6.33 | 5.63 | 9.79 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 23.70 | 23.59 | 24.50 | 11.57 | 10.23 | 15.10 |
| FCF / sales %i | 7.80 | 8.67 | 7.37 | 5.61 | 5.89 | 4.89 |
| Current ratioi | 1.62 | 1.27 | 1.32 | 1.75 | 1.79 | 1.86 |
| Quick ratioi | 1.26 | 0.98 | 1.03 | 1.40 | 1.33 | 1.44 |
| Debt / assetsi | 17.03 | 16.45 | 14.95 | 15.76 | 15.24 | 16.44 |
| LT debt / equityi | 25.31 | 15.86 | 15.40 | 22.60 | 22.84 | 22.80 |
| Interest coveragei | 4.57 | 6.49 | 7.19 | 4.79 | 9.66 | 14.77 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Automotive is the largest reported line at 23.14% of revenue, across 9 reported segments.
- No single line clears half of revenue; Kaplan international is next at 19.38%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Automotive23.14%
Kaplan international19.38%
CSI Pharmacy Holding Company, LLC (CSI)11.40%
Manufacturing10.23%
Television Broadcasting8.42%
Other Healthcare7.61%
Other Businesses and Corporate Office Revenues7.18%
Higher education6.63%
Supplemental education6.10%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.